These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 28554757

  • 1. Clinicopathological significance and prognostic role of EZH2 expression in non-small cell lung cancer.
    Kim NY, Pyo JS.
    Pathol Res Pract; 2017 Jul; 213(7):778-782. PubMed ID: 28554757
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis.
    Fan K, Zhang CL, Qi YF, Dai X, Birling Y, Tan ZF, Cao F.
    Biomed Res Int; 2020 Jul; 2020():2380124. PubMed ID: 33299862
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Peroxiredoxin 4 as an independent prognostic marker for survival in patients with early-stage lung squamous cell carcinoma.
    Hwang JA, Song JS, Yu DY, Kim HR, Park HJ, Park YS, Kim WS, Choi CM.
    Int J Clin Exp Pathol; 2015 Jul; 8(6):6627-35. PubMed ID: 26261544
    [Abstract] [Full Text] [Related]

  • 9. Expression of caveolin-1 is correlated with disease stage and survival in lung adenocarcinomas.
    Zhan P, Shen XK, Qian Q, Wang Q, Zhu JP, Zhang Y, Xie HY, Xu CH, Hao KK, Hu W, Xia N, Lu GJ, Yu LK.
    Oncol Rep; 2012 Apr; 27(4):1072-8. PubMed ID: 22200856
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C, Hao K, Hu H, Sheng Z, Yan J, Wang Q, Yu L.
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Expression of SIRT1 and cortactin is associated with progression of non-small cell lung cancer.
    Noh SJ, Baek HA, Park HS, Jang KY, Moon WS, Kang MJ, Lee DG, Kim MH, Lee JH, Chung MJ.
    Pathol Res Pract; 2013 Jun; 209(6):365-70. PubMed ID: 23702379
    [Abstract] [Full Text] [Related]

  • 14. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
    Huqun, Ishikawa R, Zhang J, Miyazawa H, Goto Y, Shimizu Y, Hagiwara K, Koyama N.
    Cancer; 2012 Mar 15; 118(6):1599-606. PubMed ID: 21837672
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer.
    Grah JJ, Katalinic D, Juretic A, Santek F, Samarzija M.
    Tumori; 2014 Mar 15; 100(1):60-8. PubMed ID: 24675493
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.